MetLife (NYSE:MET – Get Free Report) had its price target increased by equities research analysts at TD Cowen from $97.00 to $99.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the financial services provider’s stock. TD Cowen’s price objective points to a potential upside of 11.64% from the stock’s current price.
Several other research firms have also issued reports on MET. Barclays lowered their price target on MetLife from $91.00 to $90.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. StockNews.com upgraded shares of MetLife from a “hold” rating to a “buy” rating in a report on Monday. Jefferies Financial Group lifted their target price on MetLife from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, September 27th. Piper Sandler upped their price target on MetLife from $85.00 to $92.00 and gave the company an “overweight” rating in a report on Wednesday, October 2nd. Finally, Morgan Stanley reduced their price objective on MetLife from $86.00 to $85.00 and set an “overweight” rating for the company in a report on Monday, August 19th. Fourteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $88.62.
Get Our Latest Report on MetLife
MetLife Stock Up 1.0 %
Institutional Investors Weigh In On MetLife
Institutional investors have recently made changes to their positions in the company. Great Valley Advisor Group Inc. increased its stake in MetLife by 1.3% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 9,464 shares of the financial services provider’s stock worth $781,000 after buying an additional 123 shares during the period. Abacus Planning Group Inc. raised its stake in shares of MetLife by 1.0% during the third quarter. Abacus Planning Group Inc. now owns 12,301 shares of the financial services provider’s stock valued at $1,015,000 after acquiring an additional 127 shares in the last quarter. First Commonwealth Financial Corp PA boosted its holdings in shares of MetLife by 0.8% in the third quarter. First Commonwealth Financial Corp PA now owns 16,675 shares of the financial services provider’s stock valued at $1,375,000 after purchasing an additional 133 shares during the period. Avestar Capital LLC increased its holdings in MetLife by 3.2% during the 3rd quarter. Avestar Capital LLC now owns 4,264 shares of the financial services provider’s stock worth $352,000 after purchasing an additional 133 shares during the period. Finally, Financial Management Professionals Inc. raised its position in MetLife by 2.0% during the 3rd quarter. Financial Management Professionals Inc. now owns 6,984 shares of the financial services provider’s stock valued at $576,000 after purchasing an additional 136 shares in the last quarter. Institutional investors own 89.81% of the company’s stock.
About MetLife
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Further Reading
- Five stocks we like better than MetLife
- Trading Stocks: RSI and Why it’s Useful
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.